EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: A positive association

Lung Cancer

Volumn 62, Issue 1, 2008, Pages 35-44

  Berghmans, T ^a   Mascaux, C ^a,b   Haller, A ^a   Meert, A P ^a   Van Houtte, P ^a   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b FUND FOR SCIENTIFIC RESEARCH   (Belgium)

Author keywords

EGFR; Mdm2; Non small cell lung cancer; p53; Prognosis; Stage III; Staging; TTF 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN MDM2; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 52149096659     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.02.003     Document Type: Article

References (51)

1. Graziano S.L. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 17 Suppl. 1 (1997) S37-S58
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
3. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2 (2007) 706-714
4. Andre F., Grunenwald D., Pignon J.P., Dujon A., Pujol J.L., Brichon P.Y., et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18 (2000) 2981-2989
5. Bollen E.C., Theunissen P.H., van Duin C.J., Drenth B.M., van Noord J.A., and Blijham G.H. Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer. Scand J Thorac Cardiovasc Surg 28 (1994) 97-102
6. Inoue K., Sato M., Fujimura S., Sakurada A., Takahashi S., Usuda K., et al. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 116 (1998) 407-411
7. Jassem J., Skokowski J., Dziadziuszko R., Jassem E., Szymanowska A., Rzyman W., et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 119 (2000) 1141-1146
8. Leong S.S., Rocha Lima C.M., Sherman C.A., and Green M.R. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed?. Chest 115 (1999) 242-248
9. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 63 (1997) 1441-1450
10. Berghmans T., Lafitte J.J., Thiriaux J., VanHoutte P., Lecomte J., Efremidis A., et al. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. Lung Cancer 45 (2004) 339-348
11. Sculier J.P., Paesmans M., Ninane V., Giner V., Bureau G., Lafitte J.J., et al. Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party. Lung Cancer 22 (1998) 201-213
12. Kanters S.D., Lammers J.W., and Voest E.E. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8 (1995) 1389-1397
13. Sculier J.P., Paesmans M., Libert P., Bureau G., Dabouis G., Thiriaux J., et al. Facteurs pronostiques dans le cancer bronchique non à petites cellules avancé: expériences de l'European Lung Cancer Working Party. Rev Mal Respir 14 (1997) 445-449
14. D'Amico T.A., Massey M., Herndon J.E., Moore M.B., and Harpole Jr. D.H. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
15. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15 (1997) 2858-2865
16. Langendijk H., Thunnissen E., Arends J.W., de J.J., ten V.G., Lamers R., et al. Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol 56 (2000) 197-207
17. Langendijk J.A., Thunnissen F.B., Lamers R.J., de Jong J.M., ten Velde G.P., and Wouters E.F. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol 36 (1995) 218-224
18. Lee T.K., Horner R.D., Silverman J.F., Chen Y.H., Jenny C., and Scarantino C.W. Morphometric and morphologic evaluations in stage III non-small cell lung cancers. Prognostic significance of quantitative assessment of infiltrating lymphoid cells. Cancer 63 (1989) 309-316
19. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., and Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50 (2005) 211-219
20. Broermann P., Junker K., Brandt B.H., Heinecke A., Freitag L., Klinke F., et al. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 94 (2002) 2055-2062
21. Spierings D., de Vries E., Timens W., Groen H.J., Boezen H., and de Jong J. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9 (2003) 3397-3405
22. Uramoto H., Osaki T., Inoue K., Taga S., Takenoyama M., Hanagiri T., et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35 (1999) 1462-1465
23. Berghmans T., Meert A.P., Martin B., Ninane V., and Sculier J.P. Prognostic role of EGF-Receptor in stage III non-small cell lung cancer. Eur Respir J 25 2 (2005) 329-335
24. Berghmans T., Mascaux C., Martin B., Ninane V., and Sculier J.P. Prognostic role of p53 in stage III non-small cell lung cancer. Anticancer Res 25 (2005) 2385-2389
25. Berghmans T., Mascaux C., Martin B., Ninane V., and Sculier J.P. Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer 52 (2006) 219-224
26. Eymin B., Gazzeri S., Brambilla C., and Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 21 (2002) 2750-2761
27. Berghmans T., Paesmans M., Mascaux C., Martin B., Meert A.P., Haller A., et al. Thyroid transcription factor 1-a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 17 (2006) 1673-1676
28. Meert A.P., Martin B., Delmotte P., Berghmans T., Lafitte J.J., Mascaux C., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20 (2002) 975-981
29. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18 (2001) 705-719
30. Aikawa H., Sato M., Fujimura S., Takahashi H., Endo C., Sakurada A., et al. MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int J Mol Med 5 (2000) 631-633
31. Dworakowska D., Jassem E., Jassem J., Peters B., Dziadziuszko R., Zylicz M., et al. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer 43 (2004) 285-295
32. Dworakowska D., Jassem E., Jassem J., Karmolinski A., Dworakowski R., Wirth T., et al. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. J Cancer Res Clin Oncol 131 (2005) 617-623
33. Higashiyama M., Doi O., Kodama K., Yokouchi H., Kasugai T., Ishiguro S., et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75 (1997) 1302-1308
34. Ko J.L., Cheng Y.W., Chang S.L., Su J.M., Chen C.Y., and Lee H. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer 89 (2000) 265-270
35. Wang Y.C., Lin R.K., Tan Y.H., Chen J.T., Chen C.Y., and Wang Y.C. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol 23 (2005) 154-164
36. de Jong J.S., van Diest P.J., van d V., and Baak J.P. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 184 (1998) 53-57
37. Tanaka H., Yanagisawa K., Shinjo K., Taguchi A., Maeno K., Tomida S., et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 67 (2007) 6007-6011
38. Makoto O., Tomofumi I., and Yutaka Y. Unique cellular features in atypical adenomatous hyperplasia of the lung: ultrastructural evidence of its cytodifferentiation. Ultrastruct Pathol 25 (2001) 367-373
39. Awaya H., Takeshima Y., Furonaka O., Kohno N., and Inai K. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 58 (2005) 1076-1080
40. Meert A.P., Verdebout J.M., Martin B., Ninane V., Feoli F., and Sculier J.P. Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. Eur Respir J 21 (2003) 611-615
41. Rusch V., Klimstra D., Linkov I., and Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 55 (1995) 1365-1372
42. Martin B., Verdebout J.M., Mascaux C., Paesmans M., Rouas G., Verhest A., et al. Expression of p53 in preneoplastic and early neoplastic bronchial lesions. Oncol Rep 9 (2002) 223-229
43. Brambilla E., Gazzeri S., Lantuejoul S., Coll J.L., Moro D., Negoescu A., et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 4 (1998) 1609-1618
44. Mascaux C., Haller A., Martin B., Feoli F., Ninane V., and Sculier J.P. Early lung carcinogenesis: MDM2 expression in bronchial preneoplastic lesions and its correlation with p53. Lung Cancer 49 Supplement 2 (2005) S5
45. Graziano S.L., Tatum A., Herndon J.E., Box J., Memoli V., Green M.R., et al. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33 (2001) 115-123
46. Brooks K.R., To K., Joshi M.B., Conlon D.H., Herndon J.E., D'Amico T.A., et al. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 76 (2003) 187-193
47. Rusch V., Klimstra D., Venkatraman E., Oliver J., Martini N., Gralla R., et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55 (1995) 5038-5042
48. Sculier J.P., Paesmans M., Lafitte J.J., Baumohl J., Thiriaux J., van Cutsem O., et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 10 (1999) 295-303
49. Sculier J.P., Lafitte J.J., Berghmans T., van Houtte P., Lecomte J., Thiriaux J., et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol 15 (2004) 399-409
50. Meert A.P., Martin B., Verdebout J.M., Paesmans M., Lothaire P., Bosschaerts T., et al. Corrélation entre l'expression d'EGFR dans les biopsies et les pièces chirurgicales des cancers bronchiques. Rev Mal Respir 20 (2003) 347-353
51. Meert A.P., Martin B., Verdebout J.M., Paesmans M., Berghmans T., Ninane V., et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 44 (2004) 295-301